Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D.
O'Brien T, et al.
Neoplasia. 2013 Dec;15(12):1314-29. doi: 10.1593/neo.131718.
Neoplasia. 2013.
PMID: 24403854
Free PMC article.